###begin article-title 0
###xml 111 116 <span type="species:ncbi:9606">human</span>
Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 214 219 <span type="species:ncbi:9606">human</span>
LIM and SH3 protein 1 (LASP-1), initially identified from human breast cancer, is a specific focal adhesion protein involved in cell proliferation and migration, which was reported to be overexpressed in 8-12 % of human breast cancers and thought to be exclusively located in cytoplasm.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 137 142 <span type="species:ncbi:9606">human</span>
In the present work we analyzed the cellular and histological expression pattern of LASP-1 and its involvement in biological behavior of human breast cancer through correlation with standard clinicopathological parameters and expression of c-erbB2 (HER-2/neu), estrogen- (ER) and progesterone-receptors (PR). For this purpose immunohistochemical staining intensity and percentage of stained cells were semi-quantitatively rated to define a LASP-1 immunoreactive score (LASP-1-IRS). LASP-1-IRS was determined in 83 cases of invasive ductal breast carcinomas, 25 ductal carcinomas in situ (DCIS) and 18 fibroadenomas. Cellular LASP-1 distribution and expression pattern was visualized by immunofluorescence and confocal microscopy and assessed through separate Western blots of nuclear and cytosol preparations of BT-20, MCF-7, MDA-MB231, and ZR-75/1 breast cancer cells.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
Statistical analysis revealed that the resulting LASP-1-IRS was significantly higher in invasive carcinomas compared to fibroadenomas (p = 0.0176). Strong cytoplasmatic expression of LASP-1 was detected in 55.4 % of the invasive carcinomas, which correlated significantly with nuclear LASP-1-positivity (p = 0.0014), increased tumor size (p = 0.0159) and rate of nodal-positivity (p = 0.0066). However, levels of LASP-1 expression did not correlate with average age at time point of diagnosis, histological tumor grading, c-erbB2-, ER- or PR-expression.
###end p 7
###begin p 8
Increased nuclear localization and cytosolic expression of LASP-1 was found in breast cancer with higher tumor stage as well as in rapidly proliferating epidermal basal cells. Confocal microscopy and separate Western blots of cytosolic and nuclear preparations confirmed nuclear localization of LASP-1.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 285 293 <span type="species:ncbi:9606">patients</span>
The current data provide evidence that LASP-1 is not exclusively a cytosolic protein, but is also detectable within the nucleus. Increased expression of LASP-1 in vivo is present in breast carcinomas with higher tumor stage and therefore may be related with worse prognosis concerning patients' overall survival.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 274 277 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 444 445 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 446 447 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 52 57 <span type="species:ncbi:9606">women</span>
###xml 106 111 <span type="species:ncbi:9606">women</span>
Breast cancer is the most frequent malignancy among women and ranks first as cause of cancer deaths among women at ages between 20 to 59 years [1]. Despite the use of endocrine therapy, systemic chemotherapy and novel approaches such as treatment with trastuzumab (Herceptin(R)), outcome of metastatic breast cancer has not substantially improved. Metastatic disease remains generally incurable with a median survival time of only a few years [2,3]. Thus, new therapeutic modalities are required to improve the outcome. Genes that are overexpressed in metastatic cancer cells are promising targets for novel therapeutic agents.
###end p 12
###begin p 13
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 199 204 <span type="species:ncbi:9606">human</span>
The LIM and SH3 domain protein LASP-1 was initially identified from a cDNA library of breast cancer metastases. The gene was mapped to human chromosome 17q21 in a region that is altered in 20-30% of human breast cancers [4,5], suggesting that it could play a role in tumor development and metastases of breast cancer.
###end p 13
###begin p 14
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human LASP-1 encodes a membrane-bound protein of 261 amino acids containing one N-terminal LIM domain, followed by two actin-binding sites and a C-terminal src homology SH3 domain. The actin-binding domains in the core of LASP-1 mediate an interaction between LASP-1 and actin at cell membrane extensions, but not along actin stress fibers [6-10].
###end p 14
###begin p 15
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Recent data showed an additional interaction of LASP-1 via its nebulin like actin-binding repeats with kelch related protein 1 (Krp1), a focal adhesion protein involved in cell migration. The exact cellular function of LASP-1 is not known yet, but the protein has previously been reported to localize within multiple sites of dynamic actin assembly such as focal contacts, focal adhesions, lamellipodia, membrane ruffles and pseudopodia [4,7,11-13].
###end p 15
###begin p 16
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
The C-terminal SH3 domain of LASP-1 is involved in protein-protein interactions through binding to proline-rich sequences, specifically with zyxin, palladin, lipoma preferred partner (LPP) and vasodilator stimulated phosphoprotein (VASP) [9,14,15]. Mutation analysis of LASP-1 led to the conclusion that its SH3 domain is necessary for pseudopodial extension and invasion [16].
###end p 16
###begin p 17
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Although no binding partner for the LIM domain of LASP-1 has been identified so far, previous data have shown that the zinc-finger module in the LIM domain of LASP-1 is an morphologically and perhaps functionally independent folding-unit of this protein harboring the possibility of direct binding to DNA [17].
###end p 17
###begin p 18
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Moreover, LASP-1 is substrate of Abelson tyrosine kinase. Abelson tyrosine kinase is strongly involved in carcinogenesis of hematopoetic tumors, such as B-cell lymphomas [18]. Phosphorylation of LASP-1 at tyrosine 171 is associated with loss of LASP-1 from focal adhesion points and the initiation of cell death, but without changes in dynamics of migratory processes [13]. In addition, phosphorylation of LASP-1 at serine 146 by cAMP- and cGMP-dependent protein kinases resulted in a translocation of the protein from membrane to cytosol and was followed by reduced cell migration [8]. All these protein-protein interactions mediated by the LIM and SH3 domains can be regarded as scaffolds for the formation of higher order complexes and suggest that LASP-1 could be part of important signaling pathways and a structural protein as well.
###end p 18
###begin p 19
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
LASP-1 expression has been reported to be increased in metastatic breast cancer, suggesting that overexpression of LASP-1 may be involved in the migratory process of these cells [4]. Interestingly, knock-down of LASP-1 by RNA-interference in metastatic breast cancer cell lines BT-20 and MCF-7, as well as in the ovarian cancer cell line SKOV-3 resulted in a strong inhibition of proliferation, migration and in cell cycle arrest in G2-phase without induction of apoptosis or necrosis. Furthermore, LASP-1 silencing was accompanied by a reduced binding of the LASP-1 binding partner zyxin to focal contacts.
###end p 19
###begin p 20
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 71 91 <span type="species:ncbi:9310">Potorous tridactylis</span>
Reversely, artificial overexpression of LASP-1 in non-neoplastic PTK2 (Potorous tridactylis kidney) cells hardly expressing endogenous LASP-1, resulted in a acceleration of migration [19,20].
###end p 20
###begin p 21
###xml 347 352 <span type="species:ncbi:9606">human</span>
In this study we demonstrate that LASP-1 is not only a cytosolic, but also a nuclear located protein, which is highly overexpressed in breast cancer tissue compared to benign fibroadenomas. Furthermore, we provide evidence that its cytosolic overexpression and nuclear localization correlates significantly with tumor size and nodal-positivity of human breast carcinomas.
###end p 21
###begin title 22
Methods
###end title 22
###begin title 23
Tissue samples
###end title 23
###begin p 24
The studies were performed with approval of the Ethics Committee of the University of Wuerzburg. Paraffin embedded tissue samples of 126 archival cases with confirmed histological diagnosis were obtained from the department of Pathology of the University of Wuerzburg.
###end p 24
###begin p 25
We analyzed 25 cases of ductal carcinoma in situ without any invasive component (DCIS), 83 invasive ductal breast carcinomas and 18 fibroadenomas as well as three samples of normal breast tissue from reduction mammoplasty.
###end p 25
###begin p 26
###xml 495 497 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 571 573 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
The patients with invasive breast carcinomas were aged from 32 to 96 (mean 58.6 +/- 13.52) years. In this study all carcinomas, which were mainly collected from patients undergoing wide excisions, have been classified according to criteria of the WHO and recorded as invasive ductal carcinomas by a pathologist. Grading of malignancy of ductal carcinomas was evaluated according to the Scarff, Bloom and Richardson criteria with guidelines as suggested by Nottingham City Hospital Pathologists [21]. Tumor staging was performed according to parameters of the TNM system [22].
###end p 26
###begin title 27
Immunohistochemistry
###end title 27
###begin p 28
###xml 690 691 689 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 776 782 <span type="species:ncbi:9986">rabbit</span>
For immunohistochemical staining procedures tissue sections were cut from regular paraffin embedded tissue at 2-3 mum. Sections were placed onto APES (3-amino-propyltriethoxy-silane; Roth, Karlsruhe, Germany) coated slides, dewaxed in xylene, rehydrated in graded ethanol and in TRIS-buffered saline (TBS; 25 mM TRIS/HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl). For antigen retrieval, sections were subjected to heat pretreatment by boiling it in 0.01 M of sodium citrate buffer (pH 6.0) for 10 min in a microwave oven (600Watt/sec.). Endogenous peroxidase was blocked by incubation in 0.1% hydrogen peroxide in PBS for 5 min. Slides were then incubated with the polyclonal anti-LASP-1 antibody [8] diluted 1:1000 in "antibody diluent" (DAKO, Hamburg, Germany) followed by EnVision/rabbit detection system (DAKO, Hamburg, Germany). 3,3'-Diaminobenzidine (DAB; DAKO, Hamburg, Germany) was used as chromogen and sections were counterstained in hematoxylin (Mayers, Sigma, Deisenhofen, Germany), dehydrated through graded ethanol and embedded in Entelan (Merck, Darmstadt, Germany).
###end p 28
###begin title 29
Evaluation of immunohistochemical LASP-1 staining and LASP-1-IRS
###end title 29
###begin p 30
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
To assess the role of LASP-1 in human breast cancer, we examined its expression in 83 breast carcinoma samples from patients selected randomly from January 2000 to December 2006 with or without invasive components.
###end p 30
###begin p 31
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Semi-quantitative evaluation of LASP-1 immunostaining was carried out by three independent observers (TG, UK and EB) through defining of the percentage of positive cells and the staining intensity as described below. In most of all cases (> 90%) the independently determined LASP-1-IRS was consistent within all observers. In the rare event of divergent evaluation, a consensus was found. For positive controls we used breast cancer sections previously described as highly LASP-1-positive [19]. In negative controls with omitted primary antibody or with pre-immune serum no staining was observed.
###end p 31
###begin p 32
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Scoring of cytosolic LASP-1 expression was carried out in analogy to scoring of hormone receptor Immune Reactive Score (IRS) ranging from 0-12 according to Remmele et al. [23], which is used routinely in surgical pathology for the quantification of hormone receptor expression in mammary carcinoma.
###end p 32
###begin p 33
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
The percentage of LASP-1-postitive stained cells was scored in five grades (grade 0 = 0-19%, grade 1 = 20-39%, grade 2 = 40-59%, grade 1 = 60-79% and grade 4 = 80-100% LASP-1 expressing tumor cells). The fraction of LASP-1-positive stained cells was scored after having examined 10 high-power fields (40x) of one section for each sample. In addition, the intensity of LASP-1 expression by the tumor cells was determined (grade 0 = none, grade 1 = low, grade 2 = moderate, grade 3 = strong). The multiplication of these two grading scores calculates the immunoreactive score for LASP-1 expression (LASP-1-IRS) in stained tissue (% LASP-1-positive tumor cells x staining intensity = LASP-1-IRS). Examples for the very heterogeneous LASP-1 expression in invasive breast cancer are given in Figure 1.
###end p 33
###begin p 34
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Heterogeneous LASP-1 expression in human invasive breast cancer</bold>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
Heterogeneous LASP-1 expression in human invasive breast cancer. Immunohistochemical staining of different LASP-1 expression intensity levels in human invasive breast cancer samples (DAB, brown; magnification 100x). (A+B) low LASP-1-IRS (< 5). (C+D) medium to high LASP-1-IRS (> 5).
###end p 34
###begin p 35
For better statistical discrimination samples scored with cytosolic LASP-1-IRS < 5 were classified as LASP-1-negative, those with LASP-1-IRS > 5 or higher as LASP-1-positive.
###end p 35
###begin p 36
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Nuclear LASP-1-positivity was scored by determining percentage of positive nuclei regardless of cytosolic LASP-1 expression and staining intensity. In analogy to the scoring of the proliferation marker Ki67 samples were considered as nuclear-positive (NUC+) if 10% or more cells showed nuclear staining for LASP-1 [24].
###end p 36
###begin p 37
The immunomarkers c-erbB2 (HER-2/neu), estrogen receptor (ER) and progesterone receptor (PR) assessed in this study had been previously detected by standard immunohistochemistry and were drawn from the archival database of the Department of Pathology, Wuerzburg.
###end p 37
###begin title 38
Statistical analysis
###end title 38
###begin p 39
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Graph Pad Prism software test statistics was used to assess LASP-1 expression and the categorical parameters of interest. Furthermore, multivariate non-parametric analysis was performed using Fisher's exact (F) and Mann-Whitney (M) test. In the statistical analysis invasive ductal carcinomas were sorted in groups depending on nodal-positive or nodal-negative status and small (T1 = âˆ… max. 2 cm) or larger tumor size (> T1). This dichotomous graduation was made on the basis of a recent meta-analysis stating that the most beneficial prognostic criteria are nodal-negativity and a small tumor size at time point of diagnosis [25].
###end p 39
###begin p 40
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Further stratification of our tumor samples according to extent of nodal positivity and advanced tumor size was abandoned, since there are no additional major therapeutic implications [26].
###end p 40
###begin title 41
Cell culture conditions
###end title 41
###begin p 42
###xml 128 130 128 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 222 224 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 251 253 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 595 597 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 293 299 <span type="species:ncbi:9913">bovine</span>
Cell lines (MCF-7, BT-20, MDA-MB231 and ZR-75/1) were obtained from Cell Line Services (Heidelberg, Germany) and grown at 1 x 105 cells/ml in a plastic cell culture flask in a humidified incubator at 37degreesC under 5% CO2 atmosphere in HBCA-medium [27] containing 10% heat-inactivated fetal bovine serum (PAA, Linz, Austria) and 1% streptomycin/ampicillin (Invitrogen, Karlsruhe, Germany). Cells were cultured until homogeneous morphology of cells was reached (passage 3-4) since LASP-1 belongs to a group of several differential expressed proteins that are up-regulated after later passages [28].
###end p 42
###begin title 43
Immunofluorescence and confocal imaging
###end title 43
###begin p 44
###xml 324 330 <span type="species:ncbi:9986">rabbit</span>
For confocal microscopy, cells were grown until homogenous morphology at a maximum of 70% confluence on glass chamber slides, fixed in 4% (w/v) paraformaldehyde in PBS, permeabilized with 0.1% (w/v) Triton X-100 in PBS, and then stained with affinity-purified LASP-1 antibody (1:2000) followed by secondary Cy3-labeled anti-rabbit antibody (1:500) (Dianova, Hamburg, Germany).
###end p 44
###begin p 45
Fluorescence and transmission-DIC images were recorded on a modified confocal microscope (Leica SP5, Mannheim, Germany) with a 100x NA 1.4 objective (Leica, Wetzlar, Germany). Fluorescence was detected with SP5 spectral emission setting at 570-650 nm for the Cy3 and with the DIC-transmission channel. The images were recorded with 512 x 512 pixels with lateral resolution between 90 and 200 nm and a recording rate of 400 lines per second. Each image was also line averaged 4 times and the entire frame was averaged twice for optimal signal to noise ratio. The images were converted to .tiff format and analyzed with Photoshoptrade mark software.
###end p 45
###begin title 46
Preparation of nuclear and cytosolic cell fractions
###end title 46
###begin p 47
###xml 335 337 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer cell lines were harvested at 80% confluence through trypsination. Isolation of nuclei and cytosol was carried out using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, Bonn, Germany) following the manufacturers instructions. Probes were solved in Laemmli sample buffer at a final concentration of 1 x 106 /ml and stored at -20degreesC before Western Blot electrophoresis.
###end p 47
###begin title 48
Western blot analysis
###end title 48
###begin p 49
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 397 408 <span type="species:ncbi:3704">horseradish</span>
###xml 428 432 <span type="species:ncbi:9925">goat</span>
###xml 438 444 <span type="species:ncbi:9986">rabbit</span>
For Western blotting cells were lysed in Laemmli sample buffer. Equal amounts of protein, according to cell count, were resolved by 12% SDS-PAGE. After blotting on nitrocellulose membrane and blocking with 3% nonfat dry milk in 10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% (w/v) Tween 20, the membrane was first incubated with the antibody raised against LASP-1 (1:10000) [8] followed by incubation with horseradish peroxidase-coupled goat anti-rabbit IgG (Biorad, Munich, Germany), diluted 1:5000, and visualization was done using ECL (Amersham Biosciences, Freiburg, Germany). Protein bands were visualized by autoradiography. Quantification of autoradiography signals was carried out by densitometry using the ImageJ software (NIH, Bethesda, USA).
###end p 49
###begin p 50
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
GAPDH was used as a specific cytosolic marker to exclude cytoplasmatic contamination of the nuclei preparation and was visualized by incubating NC membrane with polyclonal anti-GAPDH primary antibody (1:1000; Santa Cruz, Santa Cruz, USA). Anti Lamin A+C antibody (1: 50; Abcam, Cambridge, UK) served as a specific nuclear marker to exclude nuclear contamination in cytoplasmatic cell samples [29-31]. At least three independent experiments have been carried out and representative results are shown.
###end p 50
###begin title 51
Results
###end title 51
###begin title 52
LASP-1 is overexpressed in invasive breast cancer tissue
###end title 52
###begin p 53
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
LASP-1 expression was detected in cytoplasm of tumor cells, leukocytes, myoepithelial cells and vascular smooth muscle cells, but not in stromal cells. Immunohistochemistry clearly allowed to localize LASP-1 expression in carcinoma cells of 76 malignant breast carcinomas (91.56 %), whereas in seven patients LASP-1 could not be detected in invasive neoplastic cells. Medium to high LASP-1-IRS (>5) was observed in 46 cases (55.4%), which were considered to be LASP-1-positive, while 37 probes (44.6%) showed a low LASP-1-IRS (<5) and were considered to be LASP-1-negative (Table 1 and Figure 2B). In contrast, LASP-1 could not be detected in benign epithelial cells of reduction mammoplasty.
###end p 53
###begin p 54
Statistical analysis of LASP-1 expression in 83 breast cancer samples (in-CA), 25 ductal carcinomas in situ (DCIS) and 18 fibroadenomas (FIBRO). IRS: immune reactive score; n.s.: not significant
###end p 54
###begin p 55
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graphical illustration of statistical LASP-1 distribution.</bold>
Graphical illustration of statistical LASP-1 distribution. (A) LASP-1-IRS (immunoreactive score) is significantly higher in invasive breast carcinomas (in-Ca) compared to fibroadenomas (Fibro). Error bars represent standard deviation. (B) Distribution of LASP-1-positivity (L+) and LASP-1-negativity (L-) in fibroadenomas, DCIS and invasive breast cancer. (C+D) Positive nodal status (N+) and tumor size (>T1) correlate significantly with LASP-1-positivity. Significant statistical differences are labeled with one star (p < 0.05) or two stars (p < 0.01).
###end p 55
###begin p 56
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 523 529 523 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, 3B</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
In analogy to previous findings in myoepithelial and vascular smooth muscle cells of human breast and ovarian tissue [19,20], LASP-1 overexpression could be observed in highly proliferating epidermal basal cells (Figure 3A), while cells of non-proliferating superficial layers or dermal connective tissue cells like fibroblasts showed only weak LASP-1 expression. Interestingly, strong nuclear LASP-1-positivity could be observed in about 29% of all breast carcinomas as well as in nuclei of epidermal basal cells (Figures 3A, 3B and 3C), whereas all other breast carcinoma nuclei were negative for LASP-1 and the cells only displayed perinuclear and cytosolic LASP-1 enrichment (Figure 3D).
###end p 56
###begin p 57
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Histological expression pattern of LASP-1.</bold>
Histological expression pattern of LASP-1. Immunohistochemical staining of LASP-1 (DAB, brown, magnification 100x) in different cell types. White arrows indicate LASP-1-negative nuclei, black arrows LASP-1-positive nuclei. (A) LASP-1 is highly overexpressed in physiologically proliferating epidermal basal cells, compared to superficial epidermal strata or dermal connective tissue cells. (B+C) LASP-1 is localized abundantly in nuclei of invasive breast cancer cells compared to LASP-1-negative nuclei of stromal cells. (D) Invasive breast cancer cells with LASP-1-negative nuclei but perinuclear and cytosolic LASP-1 overexpression. (E) Nuclear and cytosolic LASP-1-positive breast cancer cells in direct neighborhood to infiltrating LASP-1-negative lymphocytes.
###end p 57
###begin p 58
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
In 89% of all tumor-samples, which were scored to be LASP-1-negative, LASP-1 was not detectable within the nucleus, while 43.5% of all LASP-1-positive specimens showed clear nuclear LASP-1 staining. Thus nuclear staining is correlated with cytosolic LASP-1 expression and significantly higher in LASP-1-positive cells compared to LASP-1-negative samples (p = 0.0014; Table 2).
###end p 58
###begin p 59
Statistical analysis of LASP-1 distribution and expression in correlation to clinicopathological and biological parameters. LASP-1 (L) protein expression was analyzed in 83 breast cancer samples. Associations with clinicopathological and biological parameters were analyzed using Mann-Whitney-test (M) and Fisher's exact test (F); n.s.: not significant.
###end p 59
###begin p 60
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
However, two samples (2.4%) showed a very high nuclear LASP-1-positivity with concurrent low cytosolic staining (Figure 3B).
###end p 60
###begin p 61
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
This nuclear staining is unlikely to be unspecific, because nuclei of other benign stromal cells like fibrocytes are LASP-1-negative, even when located right next to cancer cells (Figures 3B and 3C).
###end p 61
###begin p 62
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 105 110 <span type="species:ncbi:9606">human</span>
This observation is even more obvious in Figure 3E, showing strong LASP-1-positive nuclei and cytosol of human breast cancer cells in comparison to LASP-1-negative nuclei of neighboring infiltrating lymphocytes.
###end p 62
###begin title 63
LASP-1 expression is significantly higher in invasive breast cancer compared to fibroadenomas and is correlated with TNM-staging
###end title 63
###begin p 64
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
Comparison of average LASP-1 expression of fibroadenomas, DCIS and invasive breast cancer demonstrated that invasive cancer cells display significantly higher LASP-1 expression than fibroadenomas (p = 0.0176), as seen in Table 1 and Figure 2A. In contrast, staining intensity of LASP-1 in DCIS was not significantly higher than in fibroadenomas, but also not significantly lower than in invasive breast cancer (Table 1 and Figures 2A and 2B).
###end p 64
###begin p 65
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
To evaluate the clinical relevance of the heterogeneous LASP-1 expression, LASP-1-IRS was compared to clinicopathological and biological parameters. Positive correlations were found between LASP-1-IRS and TNM-staging regarding tumor size T (p = 0.0159) and nodal-positivity (p = 0.0066; Table 2) (Figures 2C and 2D). No correlation was found with age at time of surgery (Table 3), grading, ER- and PR-positivity and HER-2/neu-expression (Table 2).
###end p 65
###begin p 66
Statistical analysis of LASP-1 (L) expression in relation to age. FIBRO: fibroadenome (n = 18); DCIS: ductal carcinomas in situ (n = 25); in-CA: invasive breast cancer (n = 83).
###end p 66
###begin p 67
###xml 97 102 <span type="species:ncbi:9606">human</span>
To evaluate the possible relevance of LASP-1 as a prognostic marker for lymph node metastasis in human breast cancer disease, a contingency test was performed and prognostic indices were calculated. Sensitivity of LASP-1-IRS-scoring to predict node-positivity is 85% with a specificity of 36.4%, (positive and negative predictive value 73.9 vs. 51.3%, respectively).
###end p 67
###begin title 68
LASP-1 is detectable within the nucleus by confocal microscopy
###end title 68
###begin p 69
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
To further assess the cellular expression pattern of LASP-1, we performed confocal and non-confocal microscopy of immunofluorescence labeled LASP-1 in the breast cancer cell line BT-20. The immunofluorescence images showed a variable cellular expression pattern of the protein. In addition to the reported localization of LASP-1 (white arrows) to focal contacts and tips of lamellipodia (Figure 4A) [4,7,11-13], LASP-1 was detected in the cytosol (Figure 4C), perinuclear (Figures 4B and 4D) and nuclear (Figures 4B and 4E). This is in accordance to the LASP-1 localization observed in the breast tissue samples (Figure 3). A similar immunohistochemical staining pattern was detected in MCF-7 breast cancer cells and SKOV-3 ovarian cancer cells (data not shown).
###end p 69
###begin p 70
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cellular LASP-1 expression pattern visualized by confocal microscopy</bold>
Cellular LASP-1 expression pattern visualized by confocal microscopy. Non-confocal (A+B) and confocal (C-E) microscopy of LASP-1 immunostaining in BT-20 breast cancer cells revealed that LASP-1 (red) is mainly detectable in focal contacts (A) and in the cytosol (C). In addition, more than 30% of the cells show a nuclear staining (B+E), and in some cells a perinuclear localization of LASP-1 is visible (B+D).
###end p 70
###begin title 71
LASP-1 is detectable in nuclear fractions of various breast cancer cell lines by Western blotting
###end title 71
###begin p 72
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 370 375 <span type="species:ncbi:9606">human</span>
To verify the nuclear localization of LASP-1, MCF-7, BT-20, MDA-MB231 and ZR-75/1 breast cancer cells were separated in cytosolic and nuclear fractions and assessed by Western blot. Equal amounts of protein, according to cell count, were resolved by 12% SDS-PAGE and blotted on nitrocellulose membrane. As seen in Figure 5, LASP-1 is clearly detectable in the nuclei of human breast cancer cell lines MCF-7 and BT-20, while nuclei of MDA-MB231 and ZR-75/1 cells were found to be negative for LASP-1 in the nuclear fraction. GAPDH was used as a specific cytosolic marker to exclude cytoplasmatic contamination of nuclei samples during preparation. Reversely Lamin A+C served as a specific nuclear marker to exclude nuclear contamination in cytoplasmatic cell fractions (Figure 5).
###end p 72
###begin p 73
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Western Blot of nuclear and cytosolic fractions of the cancer cell lines MCF-7, BT-20, MDA-MB231 and ZR-75/1</bold>
Western Blot of nuclear and cytosolic fractions of the cancer cell lines MCF-7, BT-20, MDA-MB231 and ZR-75/1. LASP-1 is detectable in nuclear (N) as well as in cytoplasmatic (C) cell fractions of breast cell lines MCF-7 and BT-20, but not in the nucleus of MDA-MB231 and ZR-75/1 cells. GAPDH was used as a cytoplasmatic marker, Lamin A + C as nuclear markers to exclude contamination during cell fraction isolation.
###end p 73
###begin title 74
Discussion
###end title 74
###begin p 75
In the present work we investigated for the first time the expression of LASP-1 in a series of 83 invasive breast carcinomas at protein level and compared the data to clinically established breast cancer parameters. We found that the degree of immunohistochemical staining correlated significantly with nodal metastasis and tumor size but seems to be independent of other parameters such as age, grading and estrogen or progesterone receptor status.
###end p 75
###begin p 76
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
In contrast to earlier publications, demonstrating the co-amplification of the LASP-1 gene together with HER-2/neu (c-erbB2) [4,32], our statistical analysis revealed no relation between LASP-1 protein level and HER-2/neu protein expression.
###end p 76
###begin p 77
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 84 89 <span type="species:ncbi:9606">human</span>
A previous study also showed that LASP-1 mRNA is overexpressed in only 8-12% of all human breast cancers [5]. However, our immunohistochemical analysis provide evidence that the LIM and SH3 domain protein is highly expressed (LASP-1-positive) in 55.4% of all tested breast cancer samples. This discrepancy could be due to the fact that Tomasetto et al. [4] used total surgical specimens for their mRNA isolation, containing undefined amounts of LASP-1 free benign tissue, while our data focused on malign cells only.
###end p 77
###begin p 78
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 205 210 <span type="species:ncbi:9606">human</span>
Consistent with the high expression of LASP-1 in breast tumors recent data demonstrated the functional significance of LASP-1 for cancer metastasis. Silencing of LASP-1 by RNAi in highly LASP-1 expressing human breast and ovarian cancer cells led to reduced cell proliferation, migration and to cell cycle arrest in G2-phase [19,20].
###end p 78
###begin p 79
These experiments are supported by our present study proving the significantly higher expression of LASP-1 in invasive breast carcinomas compared to benign fibroadenomas. The rate of strongly LASP-1 expressing samples of invasive ductal carcinomas amounted 55.4% (LASP-1-IRS > 5). Moreover, statistical analysis provided evidence for a positive correlation of cytosolic as well as nuclear LASP-1-positivity with tumor size and nodal-positivity indicating an important role of LASP-1 in proliferation and migration.
###end p 79
###begin p 80
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
These data resemble those of another focal adhesion protein, ENAH. ENAH is a member of the ENAH/VASP protein family, which regulates cell migration and actin-cytoskeleton organization at focal contacts. Like LASP-1, ENAH is not detectable in benign breast epithelium, but is weakly expressed in low-risk benign diseases like fibroadenomas and strongly expressed in invasive breast cancers. Similar to LASP-1, there is a significant correlation of ENAH-expression and tumor size (p < 0.05) [33]. In contrast to LASP-1, siRNA induced ENAH-knock-down does not affect cell proliferation while LASP-1 silencing resulted in strong inhibition of cell growth and migration [19]. Thus, it is likely that among several focal adhesion proteins which are overexpressed in breast cancer LASP-1 has more regulative function than others.
###end p 80
###begin p 81
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
In a recent investigation, a cDNA microarray was used to establish a prognostic index for nodal-positive breast cancer [34]. Similar to our study, all 20 patients were LASP-1-positive, albeit LASP-1 was found to be one out of five genes being under-expressed in patients that died within 5 years after surgery. This is in part differing from our results demonstrating a correlation between high LASP-1 protein levels and nodal-positivity. However, in many cases there are significant discrepancies between the measured mRNA levels and protein data indicating post-transcriptional mechanism of regulation and stabilization [35].
###end p 81
###begin p 82
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
In the present work we provide evidence for LASP-1 being not only a cytosolic, but also a nuclear protein. By our immunohistochemical stainings LASP-1 was detectable in nuclei of 29% of all investigated breast carcinomas independent of its actual cytosolic expression. Images taken with confocal microscopy confirmed nuclear localization of LASP-1 within the nucleus in BT-20 and MCF-7 breast cancer cells. Although these monoclonal cell lines are genetically identical, immunostaining demonstrated a variable cytosolic and nuclear LASP-1 localization, possibly dependent on cell cycle. Western blot analysis verified nuclear LASP-1 localization in MCF-7 and BT-20 cells while breast cancer cell lines MDA-MB231 and ZR-75/1 only displayed a cytosolic but no nuclear LASP-1 localization. Cell line ZR-75/1 is known to be highly estrogen and progesterone dependent [36] and was found to have the highest c-erbB2-expression among eight characterized breast- and four ovarian-cancer cell lines [37], whereas MDA-MB231 cells are ER- and PR-receptor negative and express HER-2/neu only at very low levels [38]. However, in our study LASP-1-IRS as well as nuclear LASP-1-positivity did not correlate with ER-, PR- or HER-2/neu-expression.
###end p 82
###begin p 83
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
Previous data have shown that the zinc-finger containing LIM domain of LASP-1 is a morphologically and perhaps functionally independent folding-unit offering the possibility of direct binding to DNA [17]. In general, LIM domains are specialized double zinc-finger motifs interacting with many different proteins in association with the cytoskeleton and even form homeodomains to become nuclear transcription factors [39,40]. No hetero- or homodimerization of LASP-1 has been reported yet [9]. However, LASP-1 binding partner zyxin is a LIM domain containing protein known to be a nuclear shuttle protein involved in cell migration and cell cycle control [41,42], which could act as a potential interaction partner of LASP-1 in cell core.
###end p 83
###begin p 84
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
In our present study we could demonstrate that LASP-1 is not only highly expressed in fast proliferating malignant tumor cells, but also in proliferating regenerative epidermal basal cells, while slowly proliferating dermal fibroblasts are LASP-1-negative. This observation is consistent with previous findings showing that LASP-1 expression positively influences tumor cell proliferation [19,20]. However, preliminary results show no correlation between the well-known proliferation marker Ki67 and LASP-1 expression (data not shown). Nevertheless, previous publications have shown that Ki67 expression is often considered as false positive and is inferior in evaluating tumor proliferation activity compared to standardized mitotic index at optimal cut-off points. This implies that evaluation of patients' prognosis by Ki67 expression has to be appraised with caution [43].
###end p 84
###begin p 85
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
Further statistical calculations with contingency tests demonstrated that according to our data, postoperative relevance of LASP-1 expression for prediction of nodal-positivity has a sensitivity of about 85%, suggesting that LASP-1 could be used as a predictive marker for lymph node metastasis together with other markers like the superior method of sentinel lymph node biopsy with an average sensitivity of about 95% [44]. Thus postoperative non-invasive LASP-1 scoring in primary tumor tissue could accomplish node-positivity prediction as an additional marker to invasive sentinel node biopsy, especially in cases of negative sentinel node biopsy or if patients reject invasive sentinel node biopsy.
###end p 85
###begin title 86
Conclusion
###end title 86
###begin p 87
###xml 179 184 <span type="species:ncbi:9606">human</span>
This study is the first description of LASP-1 as a nuclear protein, whose cytosolic expression and nuclear localization correlates in vivo with tumor size and nodal positivity of human invasive ductal carcinoma of the breast. In summary, our observations suggest an expanded role for LASP-1 in biological breast cancer behavior. Further prospective studies will be necessary to define the potential of LASP-1 as an independent marker for diagnosis of cancer as well as a marker for prognosis of this disease.
###end p 87
###begin title 88
Competing interests
###end title 88
###begin p 89
The author(s) declare that they have no competing interests.
###end p 89
###begin title 90
Authors' contributions
###end title 90
###begin p 91
###xml 435 443 <span type="species:ncbi:9606">patients</span>
TG, UK and AH drafted and wrote the manuscript, designed and coordinated the study, evaluated the immunohistochemical data and performed statistical analyses, EB participated in its design and carried out immunofluorescence and confocal microscopy, MK carried out the immunohistological stainings and Western blots, ME provided histopathological and immunohistological guidance, JD participated in the design of the study and provided patients' data. All authors read and approved the final manuscript.
###end p 91
###begin title 92
Pre-publication history
###end title 92
###begin p 93
The pre-publication history for this paper can be accessed here:
###end p 93
###begin p 94

###end p 94
###begin title 95
Acknowledgements
###end title 95
###begin p 96
We thank Prof. Greg Harms for the use of and help with the confocal microscope. Thanks also to Petra Thalheimer for technical assistance and Barbara Lechner for her helpful comments and corrections on the manuscript. This study was supported by Deutsche Krebshilfe 106219 to E.B. and A.H.
###end p 96
###begin article-title 97
Cancer statistics, 2005
###end article-title 97
###begin article-title 98
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
###end article-title 98
###begin article-title 99
Tamoxifen in the treatment of breast cancer
###end article-title 99
###begin article-title 100
Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains
###end article-title 100
###begin article-title 101
###xml 29 34 <span type="species:ncbi:9606">human</span>
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17
###end article-title 101
###begin article-title 102
Lasp-1, a novel type of actin-binding protein accumulating in cell membrane extensions
###end article-title 102
###begin article-title 103
Lasp-1 binds to non-muscle F-actin in vitro and is localized within multiple sites of dynamic actin assembly in vivo
###end article-title 103
###begin article-title 104
###xml 17 22 <span type="species:ncbi:9606">human</span>
Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146
###end article-title 104
###begin article-title 105
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
Phosphorylation of mouse LASP-1 on threonine 156 by cAMP- and cGMP-dependent protein kinase
###end article-title 105
###begin article-title 106
Short-term retention of actin filament binding proteins on lamellipodial actin bundles
###end article-title 106
###begin article-title 107
Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell
###end article-title 107
###begin article-title 108
The LIM and SH3 domain-containing protein, lasp-1, may link the cAMP signaling pathway with dynamic membrane restructuring activities in ion transporting epithelia
###end article-title 108
###begin article-title 109
Regulation of cell migration and survival by focal adhesion targeting of Lasp-1
###end article-title 109
###begin article-title 110
Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1
###end article-title 110
###begin article-title 111
Identification of palladin isoforms and characterization of an isoform-specific interaction between Lasp-1 and palladin
###end article-title 111
###begin article-title 112
AP-1 differentially expressed proteins Krp1 and fibronectin cooperatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localization, and activity of nondifferentially expressed proteins
###end article-title 112
###begin article-title 113
Solution structure of a naturally-occurring zinc-peptide complex demonstrates that the N-terminal zinc-binding module of the Lasp-1 LIM domain is an independent folding unit
###end article-title 113
###begin article-title 114
B cell signaling and tumorigenesis
###end article-title 114
###begin article-title 115
Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells
###end article-title 115
###begin article-title 116
###xml 65 70 <span type="species:ncbi:9606">human</span>
Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation
###end article-title 116
###begin article-title 117
###xml 48 55 <span type="species:ncbi:9606">patient</span>
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement
###end article-title 117
###begin article-title 118
Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual
###end article-title 118
###begin article-title 119
[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]
###end article-title 119
###begin article-title 120
Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death
###end article-title 120
###begin article-title 121
An overview of prognostic factors for long-term survivors of breast cancer
###end article-title 121
###begin article-title 122
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
###end article-title 122
###begin article-title 123
###xml 56 61 <span type="species:ncbi:9606">human</span>
Continuous culture and soft agarose cloning of multiple human breast carcinoma cell lines in serum-free medium
###end article-title 123
###begin article-title 124
###xml 80 85 <span type="species:ncbi:9606">human</span>
A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell
###end article-title 124
###begin article-title 125
The nuclear envelope lamina is reversibly depolymerized during mitosis
###end article-title 125
###begin article-title 126
Immunocytochemical localization of the major polypeptides of the nuclear pore complex-lamina fraction. Interphase and mitotic distribution
###end article-title 126
###begin article-title 127
###xml 32 37 <span type="species:ncbi:9606">human</span>
The alpha-helical rod domain of human lamins A and C contains a chromatin binding site
###end article-title 127
###begin article-title 128
###xml 56 61 <span type="species:ncbi:9606">human</span>
Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer
###end article-title 128
###begin article-title 129
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors
###end article-title 129
###begin article-title 130
###xml 36 43 <span type="species:ncbi:9606">patient</span>
Genetic prognostic index influences patient outcome for node-positive breast cancer
###end article-title 130
###begin article-title 131
###xml 87 111 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae
###end article-title 131
###begin article-title 132
###xml 78 83 <span type="species:ncbi:9606">human</span>
Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines
###end article-title 132
###begin article-title 133
Expression of tumor markers on breast and ovarian cancer cell lines
###end article-title 133
###begin article-title 134
Relevance of breast cancer cell lines as models for breast tumours: an update
###end article-title 134
###begin article-title 135
LIM domains: multiple roles as adapters and functional modifiers in protein interactions
###end article-title 135
###begin article-title 136
The LIM domain: regulation by association
###end article-title 136
###begin article-title 137
Zyxin: zinc fingers at sites of cell adhesion
###end article-title 137
###begin article-title 138
The LIM domain: from the cytoskeleton to the nucleus
###end article-title 138
###begin article-title 139
Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index
###end article-title 139
###begin article-title 140
Evaluation of sentinel lymph nodes in breast cancer
###end article-title 140

